Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients

被引：12
|
作者：
Hifumi, Toru [1 ]
Isokawa, Shutaro [1 ]
Otani, Norio [1 ]
Ishimatsu, Shinichi [1 ]
机构：
[1] St Lukes Int Hosp, Dept Emergency & Crit Care Med, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan
来源：
CRITICAL CARE | 2020年 / 24卷 / 01期
关键词：
COVID-19; Adverse events; Nafamostat mesylate; Favipiravir;
D O I：
10.1186/s13054-020-03227-4
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Evaluation of the effect of favipiravir on patients with COVID-19
    Kamali, Alireza
    Sarmadian, Hossein
    Mahmoodiyeh, Behnam
    Valibeik, Shamim
    Farmani, Farzane
    Bashirgonbadi, Zahra
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (02) : 242 - 245
  • [32] Pharmacokinetic characterization of favipiravir in patients with COVID-19
    Gulhan, Rezzan
    Eryuksel, Emel
    Oglu, Medine Gulcebi Idriz
    Culpan, Yekta
    Toplu, Aylin
    Kocakaya, Derya
    Tigen, Elif
    Sengel, Buket Erturk
    Sili, Uluhan
    Yildizeli, Sehnaz Olgun
    Balcan, Mehmet Baran
    Elci, Abdullah
    Bulut, Cenk
    Karaalp, Atila
    Yananli, Hasan Raci
    Guner, Abdullah Emre
    Hatipoglu, Mustafa
    Karakurt, Sait
    Korten, Volkan
    Ratnaraj, Neville
    Patsalos, Philip
    Ay, Pinar
    Onat, Filiz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3516 - 3522
  • [33] Population pharmacokinetics of favipiravir in patients with COVID-19
    Irie, Kei
    Nakagawa, Atsushi
    Fujita, Hirotoshi
    Tamura, Ryo
    Eto, Masaaki
    Ikesue, Hiroaki
    Muroi, Nobuyuki
    Fukushima, Shoji
    Tomii, Keisuke
    Hashida, Tohru
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (10): : 1161 - 1170
  • [34] Hematological Malignancy Patients, COVID-19, and Favipiravir
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 331 - 332
  • [35] Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
    Korman, Tony M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)
  • [36] Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project
    Farah, Rita
    Kazzi, Ziad
    Brent, Jeffrey
    Burkhart, Keith
    Wax, Paul
    Aldy, Kim
    CLINICAL TOXICOLOGY, 2022, 60 (08) : 942 - 946
  • [37] Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
    Toshie Manabe
    Dan Kambayashi
    Hiroyasu Akatsu
    Koichiro Kudo
    BMC Infectious Diseases, 21
  • [38] Favipiravir for treating COVID-19
    Korula, Pritish
    Alexander, Hanna
    John, Jisha Sara
    Kirubakaran, Richard
    Singh, Bhagteshwar
    Tharyan, Prathap
    Rupali, Priscilla
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (02):
  • [39] The COVID-19 pandemic's impacts on adverse events associated with care
    Morgand, Claire
    Cabarrot, Philippe
    Coniel, Marie
    Prunet, Caroline
    Gloanec, Marie
    Morin, Sandrine
    May-Michelangeli, Laetitia
    Grenier, Catherine
    SANTE PUBLIQUE, 2021, 33 (06): : 959 - 970
  • [40] Favipiravir, an antiviral for COVID-19?
    Coomes, Eric A.
    Haghbayan, Hourmazd
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) : 2013 - 2014
12345